Managing Fatty Liver Disease Linked to Metabolic Problems: Current Knowledge and Future Prospects

Approximately 38% of the global population is affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with projections of 55% by 2040.

• MASLD is characterized by liver fat accumulation alongside cardiometabolic risk factors like obesity and type 2 diabetes.
• It has become a leading cause of cirrhosis and liver cancer due to its systemic nature and association with other health conditions.
• The disease is often underdiagnosed despite its increasing prevalence and clinical significance.
• Fibrosis stage is identified as the most reliable predictor of patient outcomes, including mortality rates.
• Lifestyle changes are fundamental to treatment, with medication options tailored to the patient's disease stage and other health issues.
• Resmetirom and semaglutide are the first FDA-approved medications aimed at modifying liver disease in patients with advanced fibrosis.

Simplified